Genotoxic effects of irinotecan combined with the novel platinum(II) complexes in human cancer cells

Chemico-Biological Interactions

Volumn 188, Issue 1, 2010, Pages 66-74

  Kontek, Renata ^a   Matlawska Wasowska, Ksenia ^a   Kalinowska Lis, Urszula ^b   Marciniak, Beata ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Comet assay; DNA repair; Irinotecan; Platinum(II) complexes

Indexed keywords

DICHLORIDOBIS(DIETHYLPYRIDIN 4 YLMETHYLPHOSPHONATE KAPPA NITROGEN)PLATINUM; HIGH MOBILITY GROUP PROTEIN; IRINOTECAN; PLATINUM COMPLEX; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MUTAGENIC AGENT;

ARTICLE; CANCER CELL; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; DRUG POTENTIATION; GENOTOXICITY; HUMAN; HUMAN CELL; ANALOGS AND DERIVATIVES; LUNG TUMOR; NON SMALL CELL LUNG CANCER; PATHOLOGY; TOXICITY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COMET ASSAY; DNA REPAIR; HUMANS; LUNG NEOPLASMS; MUTAGENS; ORGANOPLATINUM COMPOUNDS;

EID: 77956171735     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.07.005     Document Type: Article

References (72)

1. Douillard J.Y., Cunningham D., Roth A.D., Nawarro M., James R.D., Karasek P., Jandik P., Iveson T., Carmichael J., Alakl M., Gruia G., Awad L., Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
2. Hu Y., Villalona-Calero M.A. Irinotecan: mechanism of tumor resistance and novel strategies for modulating its activity. Ann. Oncol. 2002, 13:1841-1851.
3. Mathijssen R.H., van Alphen R.J., Verweij J., Loos W.J., Nooter K., Stoter G., Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 2001, 7:2182-2194.
4. Burgess D.J., Doles J., Zender L., Xue W., Ma B., McCombie W.R., Hannon G.J., Lowe S.W., Hemann M.T. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(26):9053-9058.
5. Smith N.F., Figg W.D., Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol. In Vitro 2006, 20:163-175.
6. Kosmidis P.A., Manegold C. Advanced NSCLC: new cytostatic agents. Lung Cancer 2003, 41:123-132.
7. Mathijssen R.H., Loos W.J., Verweij J., Sparreboom A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr. Cancer Drug Targets 2002, 2:103-123.
8. Rassool F.V. DNA double strand breaks (DSB) and non-homologous end joining (NHEJ) pathways in human leukemia. Cancer Lett. 2003, 193:1-9.
9. Barnes D.E. Non-homologous end joining as a mechanism of DNA repair. Curr. Biol. 2001, 11:455-457.
10. Hefferin M.L., Tomkinson A.E. Mechanism of DNA double-strand break repair by non-homologous end joining. DNA Repair 2005, 4(6):639-648.
11. Taylor R.R., Tang Y., Gonzalez M.V., Stratford P.W., Lewis A.L. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur. J. Pharm. Sci. 2007, 30:7-14.
12. Teicher B.A. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem. Pharmacol. 2008, 75(6):1262-1271.
13. Ferguson L.R., Pearson A.E. The clinical use of mutagenic anticancer drugs. Mutat. Res. 1996, 355:1-12.
14. Lebwohl D., Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur. J. Cancer 1998, 34:1522-1534.
15. Garattini S., La Vecchia C. Perspectives in cancer chemotherapy. Eur. J. Cancer 2001, 37:128-147.
16. Kostova I. Platinum complexes as anticancer agents, recent patents. Anti-Cancer Drug Discov. 2006, 1:1-22.
17. Galanski M., Keppler B.K. Searching for the magic bullet: anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anti-Cancer Agents Med. Chem. 2007, 7:55-73.
18. Crul M., van Waardenburg R.C.A.M., Beijnen J.H., Schellens J.H.M. DNA-based drug interactions of cisplatin. Cancer Treat. Rev. 2002, 28:291-303.
19. Jordan P., Carmo-Fonseca M. Molecular mechanism involved in cisplatin cytotoxicity. Cell. Mol. Life Sci. 2000, 57:1229-1235.
20. Kartalou M., Essigmann J.M. Recognition of cisplatin adducts by cellular proteins. Mutat. Res. 2001, 478:1-21.
21. Woźniak K., Błasiak J. Recognition and repair of DNA-cisplatin adducts. Acta Biochim. Pol. 2002, 49(3):583-596.
22. Galanski M., Jakupec M.A., Keppler B.K. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr. Med. Chem. 2005, 12:2075-2094.
23. Radulovic S., Tescic Z., Manic S. Trans-platinum complexes as anticancer drugs: recent development and future prospects. Curr. Med. Chem. 2002, 9:1611-1618.
24. Natile G., Collucia M. Current status of trans-platinum compounds in cancer therapy. Coord. Chem. Rev. 2001, 216-217:383-410.
25. Farell N., Ha T.T.B., Souchard J.P., Wimmer F.L., Cros S., Johnson N.P. Cytostatic trans-platinum(II) complexes. J. Med. Chem. 1989, 32:2240-2241.
26. Farell N., Kelland L.R., Roberts J.D., Von Beusichem M. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res. 1992, 18:5065-5072.
27. Kelland L.R., Barnard C.F.J., Evans I.G., Murrer B.A., Theobald B.R.C., Wyer S.B., Goddard P.M., Jones M., Valenti M., Bryant A., Rogers P.M., Harrap K.R. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. J. Med. Chem. 1995, 38:3016-3024.
28. 3(4-hydroxymethyl)-pyridine)]. Polyhedron 2003, 22:3379-3381.
29. Perez J.M., Fuertes M.A., Alonso C., Navarro-Ranninger C. Current status of development of trans-platinum antitumor drugs. Crit. Rev. Oncol. Hematol. 2001, 35:120-190.
30. Farell N., Povirk L.F., Dange Y., DeMasters G., Gupta M.S., Kohlhagen G., Khan Q.A., Pommier Y., Gewirtz D.A. Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells. Biochem. Pharmacol. 2004, 68:857-866.
31. Kalinowska U., Matlawska K., Checinska L., Domagala M., Kontek R., Osiecka R., Ochocki J. Synthesis, spectroscopy and antiproliferative activity of cis- and trans-platinum(II) complexes with diethyl (pyridin-4-ylmethyl)phosphate. X-ray crystal structure of trans-Pt(II) complex. J. Inorg. Biochem. 2005, 99:2024-2031.
32. Pavillard V., Agostini C., Richard S., Charasson V., Montaudon D., Robert J. Determinant of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother. Pharmacol. 2002, 49:329-335.
33. Sapra P., Zhao H., Mehlig M., Malaby J., Kraft P., Longley C., Greenberger L.M., Horak I.D. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin. Cancer Res. 2008, 14(6):1888-1896.
34. 2/TC7 colon tumor cell cultures. Biol. Pharm. Bull. 2002, 25(12):1600-1603.
35. Liao W., McNutt M.A., Zhu W.-G. The comet assay: a sensitive method for detecting DNA damage in individual cells. Methods 2009, 48:46-53.
36. Singh N.P., McCoy T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 1988, 175:184-192.
37. Końca K., Lankoff A., Banasik A., Lisowska H., Kuszewski T., Góźdź S., Koza Z., Wojcik A. A cross-platform public domain PC image-analysis program for the comet assay. Mutat. Res. 2003, 534:15-20.
38. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.C., Sasaki Y.F. Single gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 2000, 35:206-221.
39. Wozniak K., Blasiak J. In vitro genotoxicity of lead acetate: induction of single and double DNA strand breaks and DNA-protein cross-links. Mutat. Res. 2003, 534:135-142.
40. Kontek R., Drozda R., Sliwinski M., Grzegorczyk K. Genotoxicity of irinotecan and its modulation by vitamins A, C and E inhuman lymphocytes from healthy individuals and cancer patients. Toxicol. In Vitro 2010, 24:417-424.
41. Godard T., Deslandes E., Sichel F., Poul J.M., Gauduchon P. Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay. Mutat. Res. 2002, 520:47-56.
42. Kašuba V., Rozgaj R., Gamulin M., Trošić I. Assessment of Cyto/genotoxicity of irinotecan in V79 cells using the comet, micronucleus, and chromosome aberration assay. Arh. Hig. Rada Toksikol. 2010, 61(1):1-9.
43. Digkas E., Kareli D., Chrisafi S., Passadaki T., Mantadakis E., Hatzimichail A., Vargemezis V., Lialiaris T. Attenuation of cytogenetic effects by erythropoietin in human lymphocytes in vitro and P388 ascites tumor cells in vivo treated with irinotecan (CPT-11). Food Chem. Toxicol. 2010, 48(1):242-249.
44. Lialiaris T.S., Kotsiou E., Pouliliou S., Kareli D., Makrinou H., Kouskoukis A., Papachristou F., Koukourakis M. Cytoprotective activity of amifostine on cultured human lymphocytes exposed to irinotecan. Food Chem. Toxicol. 2009, 47(10):2445-2449.
45. Matlawska-Wasowska K., Rainczuk K., Kalinowska-Lis U., Osiecka R., Ochocki J. Genotoxicity of novel trans-platinum(II) complexes with diethyl (pyridin-4-ylmethyl)phosphate in human non-small cell lung cancer cells A549. Chem. Biol. Interact. 2007, 168:135-142.
46. Merk O., Reiser K., Speit G. Analysis of chromate-induced DNA-protein crosslinks with the comet assay. Mutat. Res. 2000, 471:71-80.
47. Tsunoda T., Tanimura H., Hotta T., Tani M., Iwahashi M., Ishimoto K., Tanaka H., Matsuda K., Yamaue H. In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer. J. Surg. Oncol. 2000, 73(1):6-11.
48. Kanzawa F., Koizumi F., Koh Y., Nakamura T., Tatsumi Y., Fukumoto H., Saijo N., Yoshioka T., Nishio K. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin. Cancer Res. 2001, 7(1):202-209.
49. Radić B., Vrdoljak A.L., Zeljezić D., Fuchs N., Berend S., Kopjar N. Evaluation of HI-6 oxime: potential use in protection of human acetylcholinesterase inhibited by antineoplastic drug irinotecan and its cyt/genotoxicity in vitro. Acta Biochim. Pol. 2007, 54(3):583-593.
50. Tsavaris N.B., Polyzos A., Gennatas K., Kosmas Ch., Vadiaka M., Dimitrakopoulos A., Macheras A., Papastratis G., Tsipras H., Margaris H., Papalambros E., Giannopoulos A., Koufos Ch. Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination. Chemotherapy 2002, 48(2):94-99.
51. Vanhoefer U., Rougier P., Borner M., Munoz A., Van Laethem J.-L., Sobrero A. Irinotekan in combination with new agents. EJC Suppl. 2004, 2:14-20.
52. Stathopoulos G.P., Tsavdaridis D., Malamos N.A., Rigatos S.K., Kosmas Ch., Pergantas N., Stathopoulos J.G., Xynotroulas J. Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Cancer Chemother. Pharmacol. 2005, 56(5):487-491.
53. Valle J.W., Board R.E. Cytotoxic chemotherapy for advanced, non-respectable colorectal; cancer. EJSO J. Cancer Surg. 2007, 33:S17-S23.
54. Mross K, Steinbild S., Baas F., Gmehling D., Radtke M., Voliotis M., Brendel E., Christensen O., Unger C. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur. J. Cancer 2007, 43:55-63.
55. Kosmas Ch., Tsavaris N., Syrigos K., Koutras A., Tsakonas G., Makatsoris T., Mylonakis N., Karabelis A., Stathopoulos G.P., Kalofonos H.P. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane+platinum-based regimens. Cancer Chemother. Pharmacol. 2007, 59:51-59.
56. Pectasides D., Visvikis A., Kouloubinis A., Glotsos J., Bountouroglou N., Karvounis N., Ziras N., Athanassiou A. Weekly chemotherapy with carboplatin, docetaxel and irinotekan in advanced non-small-cell-lung cancer: a phase II study. Eur. J. Cancer 2002, 38:1194-1200.
57. Marzano C, Mazzega Sbovata S., Bettio F., Michelin R.A., Seraglia R., Kiss T., Venzo A., Bertani R. Solution behaviour and biological activity of bisamidine complexes of platinum(II). J. Biol. Inorg. Chem. 2007, 12:477-493.
58. Kalinowska-Lis U., Ochocki J., Matlawska-Wasowska K. Trans geometry in platinum antitumor complexes. Coord. Chem. Rev. 2008, 252:1328-1345.
59. Baba E., Fujishima H., Kusaba H., Esaki T., Ariyama H., Kato K., Tanaka R., Mitsugi K., Shibata Y., Harada M., Nakano S. Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer. Anticancer Res. 2009, 29(5):1727-1732.
60. Kopjar N., Źeljeźić D., Vrdoljak A.L., Radić B., Ramić S., Milić M., Gamulin M., Pavlica V., Fućić A. Irinotecan toxicity to human blood cells in vitro: relationship between various biomarkers. Basic Clin. Pharmacol. Toxicol. 2007, 100:403-413.
61. Zastre J., Anantha M., Ramsay E., Bally M. Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. Cancer Chemother. Pharmacol. 2007, 60(1):91-102.
62. Kobayashi K, Bouscarel B., Matsuzaki Y., Ceryak S., Kudoh S., Fromm H. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells. Int. J. Cancer 1999, 83(4):491-496.
63. Pizzolato J.F., Saltz L.B. The camptothecins. Lancet 2003, 361:2235-2242.
64. Mathijssen R.H., Verweij J., de Jonge M.J., Nooter K., Stoter G., Sparreboom A. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J. Clin. Oncol. 2002, 20(1):81-87.
65. de Jong F.A., Mathijssen R.H., Xie R., Verweij J., Sparreboom A. Flat-fixed dosing of irinotecan; influence on pharmacokinetic and pharmacodynamic variability. Clin. Cancer Res. 2004, 10:4068-4071.
66. Evans W.E., McLeod H.L. Pharmacogenomics: drug disposition, drug targets, and side effects. N. Engl. J. Med. 2003, 348(6):538-549.
67. Gharehbaghi K, Szekeres T., Yalowitz J.A., Fritzer-Szekeres M., Pommier Y.G., Jayaram H.N. Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo. Life Sci. 2000, 68:1-11.
68. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005, 4:307-320.
69. Matlawska K., Kalinowska U., Erxleben A., Osiecka R., Ochocki J. Novel analogues of 5-fluorouracil-synthesis, X-ray crystallography and cytotoxic effects in normal human peripheral blood lymphocytes and colon adenocarcinoma HT29. Eur. J. Inorg. Chem. 2005, 15:3109-3117.
70. 2O. Pharmazie 2006, 61(5):457-460.
71. van Waardenburg R.C., de Jong L.A., van Eijndhoven M.A., Verseyden C., Pluim D., Jansen L.E., Bjornsti M.A., Schellens J.H. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. J. Biol. Chem. 2004, 279(52):54502-54509.
72. van Waardenburg R.C., de Jong L.A., van Delft F., van Eijndhoven M.A., Bohlander M., Bjornsti M.A., Brouwer J., Schellens J.H. Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons. Mol. Cancer Ther. 2004, 3(4):393-402.